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Abstract: Cannabinoid receptor 2 (CB2) has a role in the pathology of some liver diseases. Cypermethrin (CYP) is a
synthetic pyrethroid insecticide used commonly for the control of pests and vectors, and for protection of foodstuffs. In
this study, the involvement of CB2 in CYP-induced liver damage in rats was investigated. CYP was applied to rats orally at
a dose of 125 mg/kg bw per day for 14 days. CB2 agonist JWH-133 was administered by intraperitoneal injection at a dose
of 3 mg/kg bw per day for the last 4 days of CYP toxicity. JWH-133 deteriorated the liver damage induced by CYP. JWH133 increased serum hepatic enzyme activities (aspartate aminotransferase, alanine aminotransferase) in rats given CYP.
However, it decreased lipid peroxidation. There were no differences in the levels of hepatic CB2 mRNA among the groups.
CB2 receptors were expressed in a small amount in normal liver tissue. In contrast, the expression levels of CB2 in CYPtreated rats were increased in fibrocyte/fibroblast, bile duct epithelial cells, Kupffer cells, and mast cells. In conclusion,
CB2 was upregulated in the liver exposed to CYP, predominantly in hepatic fibrogenic cells. JWH-133 enhanced the CYPinduced liver damage by receptor mediated and/or nonreceptor-mediated mechanisms. CB2 antagonists may reduce the
damage. The results of the study show that CB2 might be involved in the physiopathological process of CYP-induced liver
injury and justify the need for further study.
Key words: Cannabinoid receptor type 2, CB2, cypermethrin, JWH-133, liver, rat
1. Introduction
CYP is a synthetic type II pyrethroid insecticide widely
used for the control of ectoparasites of domestic animals
and home pest control owing to its high insecticidal
potential and lower mammalian toxicity (1). CYP
shows its effect via the voltage-dependent Na+ and Ca2+
channels in the membrane of nerve cells (2–4). There
is an increasing amount of evidence suggesting toxic
effects on nontarget organisms in chronic exposure of
CYP (5,6). Several studies have shown that CYP causes
oxidative stress, biochemical changes such as increase in
activities of alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and lactate dehydrogenase
(LDH); elevation in levels of thiobarbituric acid reactive
substances (TBARS), a decrease in activities of the
antioxidant enzymes (7,8), and histopathological changes
such as vacuolar degeneration, enlarged sinusoid,

vacuole formation in hepatocytes, pleomorphism in the
nucleus, congestion, necrosis, hepatocellular hypertrophy,
multinucleated hepatocytes, mononuclear cell infiltration
(MCI), and increase in Kupffer cell numbers (2,6).
Marijuana or cannabis, whose main active ingredient
is delta-9-tetrahydrocannabinol, activates two G proteincoupled membrane receptors, named CB1 and CB2 (9–
11). CB1 is mainly expressed in the nervous system and
is less expressed in various peripheral tissues such as the
heart, gut, liver, and in cells such as endothelial cells and
adipocytes. In comparison, CB2 is largely expressed in
immune cells, tonsils, spleen, and testis. Moreover, it has
been observed to be expressed to a lesser extent in other
tissues and in cells like hepatic myofibroblasts (12).
Recent studies have shown the dysregulation of
endocannabinoid system in experimental models of
bowel, liver, and heart diseases. Evidence suggests that

* This article is summarized from the PhD thesis entitled “Investigation of the therapeutic effects of CB2 agonist JWH-133 in cyper
		 methrin toxicity induced liver damage in rats” by H. Tutun.
** Correspondence: hidayettutun@gmail.com
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selective CB2 agonists may protect against hepatic,
cerebral, and myocardial ischemia/reperfusion (I/R)
injuries (13,14). Although CB1 and CB2 are expressed at
a low level in normal livers, they are markedly upregulated
in experimental liver injury and liver cirrhosis of various
etiologies. Upregulation occurs in spindle-shaped cells,
inflammatory cells, and ductular proliferating cells. CB2
is also expressed in hepatocytes of nonalcoholic steatosis
and steatohepatitis, and in activated hepatic stellate cells
and hepatic myofibroblasts within fibrous septa (15,16).
Numerous studies have been done on the effect of
endocannabinoid system on liver diseases. Consequently,
these studies have suggested that CB1 antagonism or CB2
activation may provide a significant therapeutic benefit
(12,14). The purpose of this study was to investigate the
involvement of CB2 in CYP-induced liver damage and the
effects of JWH-133 on liver injury in rats.
2. Materials and methods
2.1. Animals
Male Sprague Dawley rats (180–240 g) were used (Ankara
University Farms, Turkey). The rats were housed under
a 12-h light/dark cycle at a constant temperature and
humidity and given access to food and water ad libitum.
The study was performed according to the European
Community Council Directive (2010/63/EU) and
approved by the Ankara University Animal Experiments
Local Ethic Board (2014-16-104).
2.2. Experimental design
CYP (Alfa Aesar) was dissolved in 1 mL of corn oil at a
dose of 125 mg/kg body weight. JWH-133 (Axon) was
freshly prepared in a vehicle solution containing 1 drop of
Tween 20 (Sigma) in 0.1 mL of dimethyl sulfoxide (Sigma)
and then diluted in NaCl 0.9%. After acclimatization, six
rats were sacrificed on the first day as negative controls
(negative control group, NCG). Then the rats were divided
into four sets. Group 1 served as controls (only vehicle and
corn oil). CYP was administered orally through gavage
to groups 2 and 3 for 14 days. The rats in groups 3 and 4
received JWH-133 (3 mg/kg, ip) for the last 4 days. Body
weights were measured daily. The rats were sacrificed after
14 days. Blood samples were taken by cardiac puncture
for liver enzymes. Liver tissues were taken, weighed, and
either fixed in buffered formalin, or rapidly frozen in dry
ice. All samples were stored at –80 °C until they were used.
2.3. Liver function tests
The blood samples were centrifuged to get serum at 4000
rpm for 10 min and the serum samples were maintained
at –80 °C until they were analyzed. The activity of AST,
ALT, and alkaline phosphatase (ALP), and the level of
glucose were measured in the serum samples collected
using a chemistry analyzer system (Cobas-C501, Roche
Diagnostics).
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2.4. Oxidative stress parameters
Liver tissues were dissected and separately homogenized
in ice-cold homogenization buffer (86.0 g of saccharose,
0.372 g of EDTA, 0.606 g of Tris in 1 L tridistilled water,
pH 7.4) for glutathione peroxidase (GPx), homogenization
buffer (50 mmol/L and Na2HPO4 2H2O in 1 L tridistilled
water, 0.5% Tween 20) for superoxide dismutase (SOD),
and RIPA buffer (Cayman; cat: 100010263) for TBARS by
using an ultrasound homogenizer (Bandelin, Sonoplus
UW 3100). The homogenates were centrifuged at 12,000 ×
g for 10 min at 4 °C. GPx was measured by the method of
Paglia and Valentine (17) using a Glutathione Peroxidase
Kit (Cayman, 703102), SOD was measured by the method
of Sun et al. (18) using a Superoxide Dismutase Assay Kit
(Cayman, 706002), TBARS was measured by the method
of Ohkawa et al. (19) using TBARS Assay Kit (Cayman,
100009055) in supernatants collected, and assays were
made according to their own protocol. Moreover, the
protein content of each extract was determined using a
Total Protein Kit (Erba; cat. BLT00054) in the autoanalyzer
(Erba XL 600, Meinheim, Germany).
2.5. Liver histopathology
Part of the liver tissue was fixed in 10% neutral-buffered
formalin for 24 h, routinely processed, and embedded
in paraffin. The paraffin blocks were cut in 5-µm-thick
sections. They were used for immunostaining and
histopathological examination. Sections were stained with
hematoxylin/eosin (HE) for routine examination. Liver
sections were assessed by a veterinary pathologist blinded
to study conditions. Slides were examined using a light
microscope and photographs were taken at the Veterinary
Department of Pathology, Ankara University, using an
automated digital camera system (Olympus CH30/Ch40,
Japan). Parenchyma degeneration and necrosis were
scored according to severity as negative (–), weak (+),
moderate (++), and severe (+++) (2).
2.6. Immunohistochemistry (IHC)
After liver sections were deparaffinized at 55 °C for
30 min during the time they were in the oven, they
were rehydrated in Tris buffered saline (TBS) (Abcam,
ab64248). Sections underwent antigen retrieval to unmask
antigens for 20 min (10% citrate buffer). Endogenous
peroxidase activity was inhibited by 3% hydrogen
peroxide (Abcam, ab64261) pretreatment for 20 min in
the dark, and then sections were preincubated in serum
blocking buffer (Abcam, ab64261) for 10 min, stained with
the primary antibody (Abcam, rabbit polyclonal anti-rat
CB2, ab45942), diluted 1:100 in antibody diluent (Abcam,
ab64211), and incubated overnight at 4 °C. After rinsing
3 times for 5 min in TBS, sections were incubated with
biotinylated secondary antibody (Abcam, rabbit specific
HRP/AEC, ab64261) for 30 min at room temperature.
Sections were rinsed 3 times for 5 min and antigen

TUTUN and BAYDAN / Turk J Vet Anim Sci
visualization was achieved with streptavidin (Streptavidin
HRP/AEC, ab64261) for 30 min at room temperature.
After they were rinsed 3 times for 4 min, sections were
incubated with AEC (3-amino-9 ethylcarbazole) (Thermo
Scientific, ta125ha) for about 1 min and counterstained
with hematoxylin (Abcam, ab128990) for about 40 s.
CB2 positive staining was visualized and photographed
using a digital microscope (Leica DM 2500). As negative
control, immunostaining was carried out without the
first antibody. As positive control, immunostaining was
performed on a spleen. Reactions were scored in terms
of severity of immunostained cells and areas as negative
(–), very weak (+), weak (++), moderate (+++), and strong
(++++) (20). Two independent observers assessed the
immunohistochemical reaction.
2.7. RNA extraction, transcription, and amplification
A commercial kit (Thermo Scientific GeneJET RNA
Purification Kit, Cat. K0731) was used for total RNA
extraction from the liver. Quantitative real-time PCR
(QRT-PCR) was performed on a QIAGEN Rotor-Gene P.
cDNA synthesis was carried out from 1 µg of total RNA
with random hexamers using RevertAid First Strand
cDNA Synthesis Kit, Thermo Scientific). QRT-PCR
primers (sense, 5’-TGACTGCTGTTGACCGATACCT-3’;
antisense, 5’-GCCGAGAGGACCCACATG-3’), and probe
(5’-Fam-CTACCTACAAAGCTCTCGTCACCCGTGGTamra-3’) were designed by Beltramo et al. (21) according
to rat CB2 gene (GenBank: AF286721). The positive control
was manufactured synthetically by a commercial firm
(SENTEGEN). QRT-PCR was carried out with Maxima
Probe qPCR Master Mix (Thermo Scientific). All samples
were run in duplicate. The reaction was carried out with
the following steps: 2 min at 50 °C; 10 min at 95 °C, once,
and 15 s at 95 °C and 1 min at 60 °C for 40 cycles (21).
Fluorescent emission for each sample was measured after
each annealing step. The positive control was employed in
each cycle as a standard for quantification.
2.8. Statistical analyses
All values are means ± SEM. All variables obtained
were examined using the Shapiro–Wilk parametric
test hypotheses for normality, and the Levene test
for homogeneity of variance. Statistical analysis was
performed using one-way analysis of variance (ANOVA).
The Duncan test was used as a post-hoc test for significant
differences between the groups. SPSS 14.01 was used.
3. Results
3.1. Morphometric parameters
There were statistically significant differences in changes
of body weight between the groups (P < 0.001). The lowest
weight gain occurred in group 3. JWH-133 significantly
reduced body weight gain in groups 3 and 4. There were

no significant differences in relative liver weight between
the groups (Table 1).
3.2. Clinical signs
Typical signs of CYP toxicity, including hypersalivation,
hypersensitivity, hunched back, scratching, ataxia, hind
limb paralysis, and convulsions were observed in rats
treated with CYP, which began 2 h after dosing. No clinical
signs were observed in groups 1 and 4. Activation of CB2
did not alleviate the typical signs of CYP toxicity in group 3.
3.3. Hepatic function tests
Compared to control group, the activities of serum AST (P
> 0.05) and ALT (P < 0.05) increased while the activities
of serum ALP (P > 0.05) decreased in group 2. There was
a reduction in the activity of serum ALP and an increase
in the activities of serums ALT and AST in group 4 when
compared to the control. Serum AST and ALT levels were
higher in group 3 in comparison with the control (Table
2). Overall, these data indicate that JWH-133 aggravates
liver damage induced by CYP.
3.4. Lipid peroxidation
Malondialdehyde (MDA) formation was measured as
TBARS material. An increase in MDA level (P > 0.05) and
a reduction in SOD (P > 0.05) and GPx (P < 0.05) activity
were observed in group 2 as compared to the control.
There was a significant decrease in SOD (P < 0.05) activity,
a small increase in GPx (P > 0.05) activity, and a reduction
in the level of MDA in group 3, as compared to group
2. Level of MDA, SOD, and GPx activities underwent a
reduction in group 4. SOD/GPx activity rate was higher
in group 2 (P < 0.05) in comparison with the other groups
(Table 3).
3.5. Immunohistochemistry
The expression of CB2 was examined by IHC with a
polyclonal antibody against rat CB2 on tissue sections
obtained from rat livers in the groups. Very weak
immunoreactivity for CB2 was detected in the liver in
the control group. In contrast, livers obtained from CYPtreated groups showed a strong CB2 immunostaining in
vena centralis and trias hepatis. CB2 expression was found
in fibroblast, biller duct epithelium, Kupffer, and mast cells
(Figure 1). A scoring of the distribution of CB2 expressed
in livers as type of cells is given in Table 4.
CB2 protein was not detected in hepatocytes. Negative
and positive control staining were performed in rat spleen
(Figure 1). CB2 protein was expressed during subacute
CYP toxicity in the rat liver.
3.6. Hepatic histopathology
Histopathologic examination of the rats in group 1 and
NGC showed normal hepatic histology (Figure 2a).
Histopathological alterations were observed in rat livers
in groups 2 and 3. Alterations ranging from moderate
degeneration (++) to necrotic were noted in group 2
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Table 1. Effects of CYP and JWH-133 on the relative body and liver weights of rats in the groups.
Parameters

Group 1 (n: 7)

Group 2 (n: 9)

Group 3 (n: 9)

Group 4 (n: 7)

Initial weight (g)

192.14 ± 31.38

195.77 ± 21. 46

179.33 ± 19.95

175.71 ± 13.53

Last weight (g)

233.71 ± 28.48

217.00 ± 19.30

193.11 ± 19.74

205.71 ± 19.77

Changes in weight (g)

41.57 ± 2.82a

21.22 ± 2.17c

13.77 ± 1.49d

30.00 ± 2.71b

Liver weight (g)

10.61 ± 1.20

11.33 ± 1.32

9.85 ± 1.87

9.91 ± 1.09

Relative liver weight

0.0454 ± 0.002

0.0521 ± 0.003

0.051 ± 0.011

0.048 ± 0.003

Values are given as mean ± SEM. (a,b,c,d). Different characters indicate statistically significant differences in the same line (P
< 0.001). Group 1: control; group 2: CYP-treated rats; group 3: CYP + JWH-133-treated rats; group 4: JWH-133-treated rats.
Table 2. Activities of liver enzymes and levels of glucose in the blood serum of rats.
NGC (n: 6)

Group 1 (n: 6)

Group 2 (n: 7)

Group 3 (n: 7)

Group 4 (n: 6)

ALP*

266.57 ± 5.32ab

280.40 ± 31.50a

269.14 ± 18.94ab

260.71 ± 10.87ab

222.33 ± 19.15b

AST**

129.57 ± 12.88b

131 ± 5.48b

149.42 ± 8.41ab

175.71 ± 18.07a

148.16 ± 7.91ab

ALT***

63.86 ± 0.96

72.16 ± 4.61

88.42 ± 3.60

88.85 ± 1.97

83.00 ± 5.02a

Glucose

–

168.42 ± 5.77

163.71 ± 6.48

165.85 ± 5.59

175.42 ± 4.54

b

b

a

a

Values are expressed as means ± SEM.
(a,b) Different characters indicate statistically significant differences in the same line (P < 0.05) for ALP and AST values.
(a,b) Different characters indicate statistically significant differences in the same line for ALT (P < 0.001).
One-way analysis of variance by Duncan test, P < 0.05, P < 0.001.
*ALP: alkaline phosphatase (IU/L), **AST: aspartate aminotransferase (IU/L), ***ALT: alanine Aminotransferase (IU/L); glucose (mg/
dL); NGC: negative control group; group 1: control; group 2: CYP-treated rats; group 3: CYP + JWH-133-treated rats; group 4: JWH133-treated rats.
Table 3. Oxidative stress parameters in male rats treated with CYP and/or JWH-133.
NGC (n: 6)

Group 1 (n: 7)

Group 2 (n: 7)

Group 3 (n: 7)

Group 4 (n: 7)

80.01 ± 5.35b

84.03 ± 7.68b

75.96 ± 1.31b

51.77 ± 3.46a

56.69 ± 5.53a

MDA

81.80 ± 5.07

77.35 ± 6.93

86.42 ± 7.21

ab

81.69 ± 6.67

61.43 ± 8.39a

GPx***

71.84 ± 5.33a

75.10 ± 1.26a

50.07 ± 7.68b

60.44 ± 4.59ab

50.45 ± 3.21b

SOD/GPx

1.13 ± 0.09

1.12 ± 0.10

1.75 ± 0.26

0.89 ± 0.10

1.13 ± 0.10b

SOD*
**

b

ab

ab

b

b

a

b

Values are expressed as means ± SEM. (a,b,c) Different characters indicate statistically significant differences in the same line (P < 0.05).
SOD*: superoxide dismutase (U/g protein); MDA**: malondialdehyde (µM/g protein); GPx***: glutathione peroxidase (U/g protein).
NGC: negative control group; group 1: control; group 2: CYP-treated rats; group 3: CYP + JWH-133-treated rats; group 4: JWH-133treated rats.

(Figures 2b and 2c). The vessels were hyperemic. Remark
cords had dissociative appearance and in places Kupffer
cells were increased in number. Focal MCI and binucleated
and giant-nucleated hepatocytes were observed in some
places (arrow). The rats showed severe parenchymal
degeneration (+++) and necrosis in the liver epithelium
cells in group 3 (Figures 2d and 2e). In addition,
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histopathological changes including perivascular roundcell infiltration, degeneration of hepatic cord, hyperemia
in veins, an increase in the number of Kupffer cells, and
giant multinucleated hepatocytes were noted. In group 4,
veins were hyperemic, especially in the sinusoids close to
the Glisson capsule, and mild parenchymal degeneration
(+) was observed in the liver epithelial cells. An increase in
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Table 4. Scoring of distribution of CB2 receptor expressed on liver as type of cells.

Hepatocyte

NGC

Group 1

Group 2

Group 3

Group 4

–

–

–

–

–

Fibroblast

+

+

++++

++++

++

Biliary duct epithelium

+

+

+++

+++

+

Kupffer cell

–

–

+++

+++

+

Mast cell

–

–

+++

+++

–

Semiquantitative scoring of staining intensities for CB2 receptor of each group.
Semiquantitative scoring of immunostaining intensities: –, negative; +, very weak; ++, weak;
+++, moderate; ++++, strong. NGC: negative control group; group 1: control; group 2: CYPtreated rats; group 3: CYP + JWH-133-treated rats; group 4: JWH-133-treated rats.

Figure 1. Representative distribution of CB2 receptor immunostaining on liver tissue sections prepared from control group (a, b),
cypermethrin-treated groups (c, d, e, f, i, j) and just JWH-133-treated group (g, h). CB2 receptors were expressed in fibroblasts (thin
arrow), bile duct epithelium (thick arrow), mast cells (arrow head) and Kupffer cells (curved arrow) in the liver. Positive control (k) and
negative control (l) in rat spleen.
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the Kupffer cell numbers and multinucleated hepatocytes
(arrows) were observed in the liver (Figure 2f). It was
observed that Kupffer cell numbers increased in groups 2,
3, and 4 as compared to the control group.
3.7. CB2 mRNA expression
The expression of CB2 in the liver was confirmed using
QRT-PCR. Liver amplification of CB2 occurred after the
23rd cycle (Figure 3). There were no statistically significant
differences in CB2 mRNA levels among the groups (P >
0.05).
4. Discussion
CYP, one of the safest pesticides used to kill a variety of
pests, can cause toxic effects due to chronic exposure
to nontarget mammals. CYP shows its toxic effects in
different pathways. These pathways include modulation
of the synthesis and release of neuromediators, oxidative
stress, DNA damage, modulation of sodium, potassium,
voltage-gated calcium, and chloride channels (3,4).
The endocannabinoid system is responsible for various

activities such as pain, inflammation, appetite, and
psychoactivity in mammals. The system creates these
effects via various receptor- and nonreceptor-mediated
pathways (22). A variety of natural or synthetic substances
bind to endocannabinoid system receptors. Recent studies
on organic phosphorus compounds have shown that these
compounds act directly on fatty acid amide hydrolase and
monoacylglycerol lipase responsible for the degradation of
endocannabinoids (23). In one study, it has been indicated
that WIN 55,212–2, CB agonist, modulates the effects of
organic phosphorous insecticides (24). In other studies,
CB2 activation has been emphasized to inhibit adenylate
cyclase (25) and increase intracellular free Ca2+ levels (26).
In the present study, JWH-133 increased the toxic effect
of CYP on the liver. This may be due to the nonreceptormediated mechanisms mentioned above.
In our study, a decrease in weight gain was observed in
the groups treated with CYP (groups 2 and 3) compared
to the control group. It has been found that CYP reduced
the weight gain in laboratory animals in similar studies

Figure 2. Light micrographs of rat livers treated as follows: control (a),
cypermethrin-treated rats (b, c), cypermethrin plus JWH-133-treated
rats (d, e), and JWH-133-treated rats (f). In group 2, moderate (++)
parenchymal degeneration was observed. In group 3, severe (+++)
parenchymal degeneration was observed. In group 4, mild (+) parenchymal
degeneration was observed.
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R e l a ti v e q u a nti ty o f C B 2
mRNA ± S EM

0.350
0.300
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0.100
0.050
0.000

NGC
Group

Group 1

Group 2

Group 3

Group 4

Figure 3. CB2 mRNA levels in groups. CB2 expression in the
liver. Amplification in NGC and control group occurred after the
23rd cycle. There was no statistically significant increase in the
level of CB2 mRNA in the groups. Data were calculated as the
mean ± SEM of the relative amount of mRNA. NGC: negative
control group; group 1: control; group 2: CYP-treated rats; group
3: CYP + JWH-133-treated rats; group 4: JWH-133-treated rats.

(5,27,28). Group 3 had less weight gain among the groups.
The reason for the slight increase in weight in group 3 may
be the fact that JWH-133 increased toxic effects of CYP on
rats. Clinical findings of sciatic nerve paralysis, salivation,
timid behavior, drowsiness, itching, ataxia, convulsions,
and hypersensitivity were observed in rats treated with
CYP. These symptoms were also observed in other similar
studies (5,28). Regarding the relative liver weight, Aldana
et al. (5) reported a 20% increase in the 7-day CYP toxicity
study. However, there were no significant changes in
relative liver weights in a 28-day CYP toxicity study (6). In
the present study, there were no significant differences in
relative liver weight among the groups.
Lipid peroxidation plays a critical role in the
pathogenesis of many human and animal diseases. In
lipid peroxidation, free radicals such as hydroxyl and
superoxide are formed and cause oxidative cell damage
(29). Cellular damage leads to impaired liver function (8).
Antioxidant enzymes are the first protection mechanisms
used to protect biological macromolecules from oxidative
damage (29). Studies have shown that oxidative tissue
damage occurs in rats and mice exposed to pyrethroids
(30,31). An increase in MDA level and a decrease in GPx
and SOD activities in liver damage caused by CYP have
been reported (7,8). These results are similar to results
obtained from rats in group 2. CB2 agonists reduce MDA
level in liver injury induced by I/R in mice (32,33). In
the present study, JWH-133 did not significantly reduce
the MDA level raised by CYP. Compared to the control
group, there was a significant decrease in the level of
MDA in group 4 (P < 0.05). Unexpectedly, significant
decreases in SOD and GPx enzyme activities in groups 3
and 4 (P < 0.05) occurred. The depletion of antioxidant
enzymes can be explained by the formation of reactive

oxygen species created by CYP, depletion of enzyme
substrate, and/or downregulation of the transcription and
translation process (34). Elevated superoxide production
caused by lipid peroxidation was normalized by SOD
and allopurinol or its metabolite oxypurinol, which are
inhibitors of xanthine oxidase (generate superoxide) in the
experimental diabetes studies in mice (35,36). In another
study, JWH-133 reduced the formation of superoxide (37).
These studies show that JWH-133 can reduce oxidative
stress by reducing the amount of superoxide. In the
present study, JWH-133 reduces the enzyme activity, and
the level of MDA in this study can be explained in two
ways: I) by reducing the formation of the superoxide by
inhibition and/or downregulation of radical-producing
oxidant enzymes (35,36); II) directly as antioxidants (Vit
E, C, etc.) reducing the superoxide formed (31,38). As a
result, antioxidant enzymes may have been downregulated
because of the reduction in the level of superoxide by
JWH-133. In some studies, researchers use the ratios
between the activities of antioxidant enzymes (SOD/
GPx) to examine oxidative stress (39,40). In the present
study, the SOD/GPx ratio in group 2 was different from
that of the other groups (P < 0.05). The lack of statistical
significance (P > 0.05) among the other groups may be due
to the oxidative stress-reducing effect of JWH-133.
It has been reported that agonists of CB2 have a
protective effect against hepatic damage by reducing
endothelial cell activation, inflammatory cytokines,
activation of inflammatory cells, adhesion, and adhesion
molecules (32,33). Thus, the antifibrogenic effect of CB2
activation on cirrhotic animals may be related to the
antiinflammatory effect. The increased inflammatory
response further increases oxidative stress and starts
a bad cycle, eventually leading to cell death and organ
dysfunction (33). In this study, according to the results,
JWH-133 reduced lipid peroxidation in normal rats, but
did not significantly reduce lipid peroxidation caused by
CYP toxicity. The decrease in oxidative stress in group 3
may be due to antiinflammatory effects by CB2 activation.
In previous studies, it has been found that serums
LDH, ALP, AST, and ALT activity increases in CYPtreated rats (5,7,8). Aldana et al. (5) reported that hepatic
enzymes had risen until the 5th day and subsequently
began to fall in rats given CYP for 7 days. In this study,
the decrease in activity of serum ALP may be due to the
development of resistance of the liver to CYP exposure.
Serums AST and ALT activity in liver damage models was
reduced by CB2 agonists (32,41,42). In the present study,
CB2 agonist JWH-133 did not alleviate CYP-induced liver
damage. In contrast, it enhanced the toxic effect of CYP
on rats. The results obtained in this study are different
from those of CCl4 and I/R liver damage models. The
differences between the results obtained in this study and
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those obtained in CCl4 and I/R liver damage models, as
well as significant decreases and increases in enzyme
activities in the mentioned studies, may be related to the
differences emerging in effects and in effect mechanisms
in comparison with damage models, and effects that are
very quick and strong.
Data related to expression of CBs in liver are scarce.
It has been previously indicated that normal liver
does not express CB2 (43,44). In contrast, strong CB2
immunostaining was shown in human cirrhotic samples
(43) and human samples with steatosis and nonalcoholic
steatohepatitis (44). Expression of CB2 was increased and
predominantly localized in the fibrous septa and portal
tracts in the cirrhotic rat liver (45) and CCl4-treated mice
liver (42). In the present study, CB2 mRNA was detected
in normal liver. There were no significant changes in CB2
mRNA expression levels among the groups. This may be
explained by the presence of lymphocytes and macrophages
that normally express the CB2 (44). In contrast, CB2
immunostaining was observed in the fibroblast cells, mast
cells, Kupffer cells, bile duct epithelium, and intravenous
leukocytes in CYP-treated liver. CB2 protein expression
was very weak (+) in the control group. It was noted that
there was no correlation between CB2 mRNA and protein
expression in this study. When compared to similar
studies, it has been shown that there is no correlation
between mRNA levels and related protein levels in many
genes (46–48). In addition, Schwanhäusser et al. (49,50)
reported that proteins (approximately 46 h) were 5 times
more stable than mRNA (9 h) in their work on mRNA
and related protein half-life. Parallel to the results of
these studies, Montecucco et al. (37) found a significant
decrease of CB2 mRNA levels in mouse hearts after 30 min
ischemia and 24 h reperfusion by comparison with hearts
from sham-operated animals. Transcription, mRNA
degradation, translation, and protein degradation are
important processes that determine protein concentration.
There was not a good agreement about the results between
RT-PCR and IHC in the present study, maybe due to taking
tissues 24 h after the last CYP treatment. The effect of CYP
may be weakened and CB2 mRNA may be destroyed at
this time. Since the degradation period of the CB2 protein
is longer than CB2 mRNA, CB2-immunopositive staining
may have been observed in IHC. In addition, there were
no significant changes in CB2 mRNA expression among
the groups, maybe due to the fact that CB2 did not express
in hepatocytes, which are the primary cells of the liver;
CB2 expressed in fibrogenic cells, which are very few in
comparison with hepatocytes in the liver.
Histopathological examination of the present study
revealed normal hepatic tissue histology in the control
group. Alterations ranging from moderate degenerative
(++) to necrotic were ascertained in group 2. Findings
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observed in this study were in agreement with those
observed in CYP toxicity studies (2,5,8,27). The role of
CB2 in liver diseases is controversial. Some studies have
indicated that CB2 activation shows protective properties
during liver damage. The effects are usually based on the
antifibrogenic or antiinflammatory effect induced by CB2
expressing liver fibrogenic cells and/or hepatic immune
cells (32,33,43). Auguet et al. (51) reported that hepatic
CB2 expression did not have significant differences
between morbidly obese with normal liver, simple
steatosis, or nonalcoholic steatohepatitis, and they also
stated a positive correlation between liver CB2 and gene
expression of adiponectin, which is an antiinflammatory
factor. Authors have reported that CB2 is a molecule with
a dual action. In another study, it has been demonstrated
that CB2 potentiates obesity-associated fatty liver (52). In
the present study, severe parenchymal degeneration (+++)
and necrosis were observed in the rats in group 3. The
pathologic condition was worse in rats treated with CYP
and JWH-133 by comparison with rats treated with CYP
only. Histopathological findings revealed a decrease in the
number of immune cells in group 3 in comparison with
group 2. Activation of CB2 may have an antiinflammatory
effect. Taken together, JWH-133 increased CYP-induced
liver toxicity in rats. Rats in group 4 showed very mild
parenchyma degeneration (+) and hyperemic vessels
(especially the sinusoids close to Glisson capsule) in liver.
Interestingly, Kupffer cell proliferation was observed in
group 4 compared to the control. Deveaux et al. (52)
reported that the infiltration of adipose tissue macrophages
was increased by JWH-133 in inflammation at an early
stage and decreased by the inhibition of CB2 in obesity. In
the present study, the increase in Kupffer cells may be due
to hepatotoxicity induced by CYP in groups 2 and 3, and
may be due to JWH-133 in group 4.
Mast cells have an important role in liver disease
processes such as cirrhosis, fibrosis, hepatitis, and
regeneration after liver injury. In both cases, the number
of mast cells usually increases (53–55). CB2 mRNA was
found in mast cells (56,57). The role of mast cells in liver I/R
injury has not been fully understood. In one study, it has
been reported that mast cells do not play a role in hepatic
I/R injury. However, mast cells may not be seen because
this study was performed in vitro, and the data were
collected 1 h after reperfusion (58). In another study, it was
found that mast cells had an important role in I/R injury,
and degranulation of mast cells increased in this injury
model (59). CB2 activation has many different effects on
mast cells. JWH-133 reduced edema induced by mast cells
(60). HU-308, which is a CB2 agonist, reduced arachidonic
acid in ear edema (61). However, application of CB1 and
CB2 agonists and antagonists to rat peritoneal mast cells
did not affect histamine release (62). In another study,
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2-arachidonoylglycerol and CP55,940 decreased mast cell
activation by being susceptible to a CB2 antagonist and
inhibition of nitric oxide and prostanoid pathways (63).
In the present study, CB2 expression was not observed in
groups 1 and 4, but it was observed in groups treated with
CYP. There is little information about the mechanisms
and internal molecules that have the ability to modulate
excessive mast cell activity. Taken together, like the
Kupffer cell, the mast cells may also have a role in the
pathophysiology of hepatic damage induced by CYP.
The increase in CB2 expression in some cells,
histopathological findings, and changes in hepatic enzyme
activities in liver damage induced by CYP showed that
JWH-133 enhances the toxic effect of CYP on rat liver.
JWH-133 reduced oxidative stress but did not reduce liver

damage. Another important consequence of this study is
the increased CB2 density in the liver in the case of CYP
toxicity. Our results suggest that CB2 (receptor mediated
or nonreceptor-mediated) might be involved in the
physiopathological process of CYP-induced liver injury
and justify the need for further study. Because the results
of this study contradict the results of studies on CB2,
the results should be confirmed by further studies to be
carried out in more detail.
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